Contribute Try STAT+ Today

Vertex Pharmaceuticals is looking to acquire “mid- and late-stage assets” to bolster its current research pipeline,  CEO Reshma Kewalramani said Monday at the virtual J.P. Morgan Healthcare Conference.

The company also sees more growth for its cystic fibrosis drug business. There are approximately 83,000 cystic fibrosis patients amenable to treatment with Vertex medicines in the U.S., Europe, Australia, and Canada, based on Vertex’s latest forecasts, an increase of 8,000 patients from its previous estimate.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!


What is it?

STAT+ is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • STAT+ Conversations
  • Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.